National Bank of Canada
DFTX

National Bank of Canada’s Definium Therapeutics DFTX Stock Holding History

National Bank of Canada’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-96
Closed -$199K – 2958
2021
Q4 		$199K Buy
+96
New +$3.06K ﹤0.01% 1471

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

National Bank of Canada's DFTX Position: Q1 2026 in Review

National Bank of Canada reduced its Definium Therapeutics (DFTX) stake by 8.5% in Q1 2026, selling an estimated $2.7K and leaving 1,708 shares worth $32.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2074.

National Bank of Canada first reported a position in DFTX in Q4 2021 and has held it in 18 quarters since. The position peaked at $244K in Q4 2021. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • National Bank of Canada held 1,708 shares of Definium Therapeutics worth $32.3K as of Q1 2026.
  • National Bank of Canada sold 159 Definium Therapeutics shares in Q1 2026, an estimated $2.7K.
  • Definium Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2074 holding.
  • National Bank of Canada first reported a position in Definium Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • National Bank of Canada's Definium Therapeutics position peaked at $244K in Q4 2021.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.